BioCentury
ARTICLE | Company News

Oxford BioMedica extends Aventis deal

June 6, 2000 7:00 AM UTC

BioMedica (LSE:OXB) extended its deal with AVE to include access to OXB's LentiVector lentiviral gene delivery vector for cardiovascular disease. AVE also exercised its option under the 1998 deal to i...